FDA Advisory Committee To Review Human Genome Sciences' Anthrax Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.S. government already has a stockpile of Human Genome Sciences' ABthrax (raxibacumab) for emergency use.
You may also be interested in...
Uncle Sam's Orders: Emergent Scores $107 Mil. For Anthrax Plant, While Bavarian Nordic Delivers On Smallpox
Government funding for the BioThrax plant suggests there are doubts other new treatments will be ready soon. But funding for the BioShield program may be reduced during congressional debate on appropriations.
Uncle Sam's Orders: Emergent Scores $107 Mil. For Anthrax Plant, While Bavarian Nordic Delivers On Smallpox
Government funding for the BioThrax plant suggests there are doubts other new treatments will be ready soon. But funding for the BioShield program may be reduced during congressional debate on appropriations.
FDA Panel Finds Animal Models Predict Human Response To HGS Anthrax Drug
Animal model results for Human Genome Sciences' raxibacumab are predictive of the biologics' ability to treat inhalation anthrax in humans, FDA's Anti-Infective Drugs Advisory Committee concluded Oct. 27, but FDA should request more evidence on whether the monoclonal antibody adds benefit to treatment with antibiotics alone